Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre
- 20 April 2019
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 78 (10), 1441-1443
- https://doi.org/10.1136/annrheumdis-2019-215455
Abstract
Janus kinases (JAKs) are intracellular tyrosine kinases which play a key role in the signal pathways of many cytokines, such as type l interferons (IFNs), interleukin-6 (IL-6), IL-12 and IL-23.1 All these cytokines participate in the pathogenesis of systemic lupus erythematosus (SLE). Hence, inhibition of JAK signals has provided an attractive therapeutic option in SLE. Tofacitinib can inhibit JAK1/JAK3 and has been proved effective in rheumatoid arthritis (RA),2 psoriatic arthritis and ulcerative colitis. Evidence in murine lupus have shown that tofacitinib can decrease the levels of anti-double-stranded (ds) DNA and proteinuria, remit nephritis and skin rash.3 A case report proved that tofacitinib could decrease anti-dsDNA levels in inactive SLE complicated by RA.4 A phase II randomised controlled trial reported modest efficacy of a JAK1/2 inhibitor, baricitinib, in ameliorating lupus arthritis.5 To better understand the efficacy of tofacitinib in SLE, we describe, to our knowledge for the first time, the efficacy of tofacitinib 5 mg …Keywords
Funding Information
- Chinese National High Technology Research and Development Program, Ministry of Science and Technology (2012AA02A513)
- Chinese National Key Research R&D Program (2008BAI59B02, 2017YFC0907601, 2017YFC0907602, 2017YFC0907603)
This publication has 6 references indexed in Scilit:
- The Jakinibs in systemic lupus erythematosus: progress and prospectsExpert Opinion on Investigational Drugs, 2018
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trialThe Lancet, 2018
- Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trialsAnnals Of The Rheumatic Diseases, 2017
- A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)Annals Of The Rheumatic Diseases, 2016
- Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular DysfunctionArthritis & Rheumatology, 2016
- Tofacitinib can decrease anti-DNA antibody titers in inactive systemic lupus erythematosus complicated by rheumatoid arthritisModern Rheumatology, 2015